Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors

D. C. U'Prichard, D. A. Greenberg, Solomon H Snyder

Research output: Contribution to journalArticle

Abstract

Binding of the alpha noradrenergic agonist [3H]clonidine and the alpha antagonist [3H]WB-4101 (2 ([2',6' dimethoxy]phenoxyethylamino)methylbenzodioxan) to rat brain membranes exhibits characteristics expected of alpha receptors for norepinephrine. Binding of both [3H]ligands is saturable, with KD values of 5.8 nM and 0.48 nM for [3H]clonidine and [3H]WB-4101, respectively. A series of catecholamines inhibits the binding of both ligands with the potency order epinephrine > norepinephrine >> isoproterenol, corresponding to the relative activities of these agents at alpha receptors in the periphery. Competition for binding is stereoselective, with (-) isomers of phenylethanolamines many times more potent than the corresponding (+) isomers. Classical alpha antagonists inhibit binding of both ligands at low concentrations, but beta antagonists are much weaker. Alpha agonists are more potent in displacing [3H]clonidine than [3H]WB-4101 binding, while alpha antagonists compete more avidly for [3H]WB-4101 sites. Partial agonist ergot alkaloids display similar affinities for the binding sites of both [3H]ligands. These findings may be explained by the existence of discrete agonist and antagonist states of the alpha receptor, which preferentially bind [3H]clonidine and [3H]WB-4101, respectively. Regional variations in the binding of both [3H]ligands in the brain are not pronounced, although levels tend to be highest in hypothalamus and cerebral cortex and lowest in cerebellum. Treatment with 6-hydroxydopamine fails to decrease the binding of either [3H]ligand, suggesting that binding occurs to postsynaptic sites.

Original languageEnglish (US)
Pages (from-to)454-473
Number of pages20
JournalMolecular Pharmacology
Volume13
Issue number3
StatePublished - 1977

Fingerprint

Central Nervous System
Clonidine
Ligands
Ergot Alkaloids
Oxidopamine
Brain
Isoproterenol
Cerebral Cortex
Cerebellum
Adrenergic Receptors
Epinephrine
Hypothalamus
Catecholamines
Norepinephrine
Binding Sites
(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane
Membranes

ASJC Scopus subject areas

  • Pharmacology

Cite this

Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors. / U'Prichard, D. C.; Greenberg, D. A.; Snyder, Solomon H.

In: Molecular Pharmacology, Vol. 13, No. 3, 1977, p. 454-473.

Research output: Contribution to journalArticle

@article{f5c9fd23aae54b2ca5d1df4b95172e18,
title = "Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors",
abstract = "Binding of the alpha noradrenergic agonist [3H]clonidine and the alpha antagonist [3H]WB-4101 (2 ([2',6' dimethoxy]phenoxyethylamino)methylbenzodioxan) to rat brain membranes exhibits characteristics expected of alpha receptors for norepinephrine. Binding of both [3H]ligands is saturable, with KD values of 5.8 nM and 0.48 nM for [3H]clonidine and [3H]WB-4101, respectively. A series of catecholamines inhibits the binding of both ligands with the potency order epinephrine > norepinephrine >> isoproterenol, corresponding to the relative activities of these agents at alpha receptors in the periphery. Competition for binding is stereoselective, with (-) isomers of phenylethanolamines many times more potent than the corresponding (+) isomers. Classical alpha antagonists inhibit binding of both ligands at low concentrations, but beta antagonists are much weaker. Alpha agonists are more potent in displacing [3H]clonidine than [3H]WB-4101 binding, while alpha antagonists compete more avidly for [3H]WB-4101 sites. Partial agonist ergot alkaloids display similar affinities for the binding sites of both [3H]ligands. These findings may be explained by the existence of discrete agonist and antagonist states of the alpha receptor, which preferentially bind [3H]clonidine and [3H]WB-4101, respectively. Regional variations in the binding of both [3H]ligands in the brain are not pronounced, although levels tend to be highest in hypothalamus and cerebral cortex and lowest in cerebellum. Treatment with 6-hydroxydopamine fails to decrease the binding of either [3H]ligand, suggesting that binding occurs to postsynaptic sites.",
author = "U'Prichard, {D. C.} and Greenberg, {D. A.} and Snyder, {Solomon H}",
year = "1977",
language = "English (US)",
volume = "13",
pages = "454--473",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors

AU - U'Prichard, D. C.

AU - Greenberg, D. A.

AU - Snyder, Solomon H

PY - 1977

Y1 - 1977

N2 - Binding of the alpha noradrenergic agonist [3H]clonidine and the alpha antagonist [3H]WB-4101 (2 ([2',6' dimethoxy]phenoxyethylamino)methylbenzodioxan) to rat brain membranes exhibits characteristics expected of alpha receptors for norepinephrine. Binding of both [3H]ligands is saturable, with KD values of 5.8 nM and 0.48 nM for [3H]clonidine and [3H]WB-4101, respectively. A series of catecholamines inhibits the binding of both ligands with the potency order epinephrine > norepinephrine >> isoproterenol, corresponding to the relative activities of these agents at alpha receptors in the periphery. Competition for binding is stereoselective, with (-) isomers of phenylethanolamines many times more potent than the corresponding (+) isomers. Classical alpha antagonists inhibit binding of both ligands at low concentrations, but beta antagonists are much weaker. Alpha agonists are more potent in displacing [3H]clonidine than [3H]WB-4101 binding, while alpha antagonists compete more avidly for [3H]WB-4101 sites. Partial agonist ergot alkaloids display similar affinities for the binding sites of both [3H]ligands. These findings may be explained by the existence of discrete agonist and antagonist states of the alpha receptor, which preferentially bind [3H]clonidine and [3H]WB-4101, respectively. Regional variations in the binding of both [3H]ligands in the brain are not pronounced, although levels tend to be highest in hypothalamus and cerebral cortex and lowest in cerebellum. Treatment with 6-hydroxydopamine fails to decrease the binding of either [3H]ligand, suggesting that binding occurs to postsynaptic sites.

AB - Binding of the alpha noradrenergic agonist [3H]clonidine and the alpha antagonist [3H]WB-4101 (2 ([2',6' dimethoxy]phenoxyethylamino)methylbenzodioxan) to rat brain membranes exhibits characteristics expected of alpha receptors for norepinephrine. Binding of both [3H]ligands is saturable, with KD values of 5.8 nM and 0.48 nM for [3H]clonidine and [3H]WB-4101, respectively. A series of catecholamines inhibits the binding of both ligands with the potency order epinephrine > norepinephrine >> isoproterenol, corresponding to the relative activities of these agents at alpha receptors in the periphery. Competition for binding is stereoselective, with (-) isomers of phenylethanolamines many times more potent than the corresponding (+) isomers. Classical alpha antagonists inhibit binding of both ligands at low concentrations, but beta antagonists are much weaker. Alpha agonists are more potent in displacing [3H]clonidine than [3H]WB-4101 binding, while alpha antagonists compete more avidly for [3H]WB-4101 sites. Partial agonist ergot alkaloids display similar affinities for the binding sites of both [3H]ligands. These findings may be explained by the existence of discrete agonist and antagonist states of the alpha receptor, which preferentially bind [3H]clonidine and [3H]WB-4101, respectively. Regional variations in the binding of both [3H]ligands in the brain are not pronounced, although levels tend to be highest in hypothalamus and cerebral cortex and lowest in cerebellum. Treatment with 6-hydroxydopamine fails to decrease the binding of either [3H]ligand, suggesting that binding occurs to postsynaptic sites.

UR - http://www.scopus.com/inward/record.url?scp=0017750409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017750409&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 454

EP - 473

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 3

ER -